Статья

Development and Evaluation of a Cost-Effective, Carbon-Based, Extended-Release Febuxostat Tablet

Israa Al‐AniFaculty of Pharmacy, PDRC, Al-Ahliyya Amman University, Amman 19328, JordanMohammad HailatFaculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, JordanDina J. MohammedFaculty of Pharmacy, PDRC, Al-Ahliyya Amman University, Amman 19328, JordanSina M. MatalqahFaculty of Pharmacy, PDRC, Al-Ahliyya Amman University, Amman 19328, JordanAlaa Azeez Abu DayahFaculty of Pharmacy, PDRC, Al-Ahliyya Amman University, Amman 19328, JordanBashar J. M. MajeedFaculty of Pharmacy, PDRC, Al-Ahliyya Amman University, Amman 19328, JordanRiad AwadFaculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, JordanLorena FilipFaculty of Pharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaWael Abu DayyihFaculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan

2024en

ABI

Аннотация

This study outlines the development of a cost-effective, extended-release febuxostat (FEB) tablet using activated charcoal as an adsorbent to enhance drug release. FEB, a BCS Class II drug, presents formulation challenges due to low solubility and high lipophilicity. We evaluated eight formulations with varying FEB-to-charcoal ratios using FTIR and DSC for physical interactions and followed USP standards for overall assessment. The optimal 1:0.25 FEB-to-charcoal ratio demonstrated a consistent 12 h zero-order release pattern. In vivo studies indicated a significantly extended plasma profile compared to immediate-release tablets. The optimal tablets demonstrated acceptable hardness and disintegration times. This innovative approach enhances patient compliance, improves bioavailability, and reduces production costs, offering a promising solution for controlled FEB delivery.

Перевод пока недоступен

Идентификаторы

DOI: 10.3390/molecules29194629

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar